Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Wins SBIR Grant to Apply Systems Bio to Proteomic Research

NEW YORK, June 27 (GenomeWeb News) - GeneGo has won a Phase I Small Business Innovation Research grant from Department of Defense to help it develop a "systems biology suite of tools for visualization and analysis of proteomics data" the company said today.

 

Under the program, GeneGo will use its MetaCore data-mining platform to study a "broad range of proteomics data types;" research the "connectivity" of these data with other '-omics' datasets; and develop "new algorithms to reconstruct protein-state specific biological networks and pathways," according to the company.


To fulfill this research, GeneGo, based in
St. Joseph, Mich., will work with the Universityof Southern California. "By integrating the conventional proteomic analysis with a well-annotated network or pathway analysis program such as Metacore, we are able to quickly and objectively evaluate our proteomic results with high confidence," said Austin Yang, assistant professor pharmaceutical sciences at USC.


The grant comes two weeks after GeneGo received a Phase I SBIR grant from the National Institute of General Medical Science to develop computational methods for reconstructing pathways in human diseases.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.